Vestal Point Capital
Latest statistics and disclosures from Vestal Point Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, QQQ, ACLX, TERN, BMRN, and represent 34.75% of Vestal Point Capital's stock portfolio.
- Added to shares of these 10 stocks: QQQ (+$215M), TERN (+$182M), BMRN (+$129M), ABVX (+$121M), ACLX (+$109M), MRK (+$82M), ARWR (+$60M), TSHA (+$45M), ABT (+$44M), DXCM (+$42M).
- Started 25 new stock positions in BCRX, QQQ, FULC, STRO, LENZ, MRK, DBVT, IMCR, BMY, MIRM.
- Reduced shares in these 10 stocks: NUVL (-$106M), ASND (-$91M), , IONS (-$70M), BDX (-$61M), RGEN (-$52M), DYN (-$52M), DNTH (-$46M), CYTK (-$40M), .
- Sold out of its positions in FOLD, Applied Therapeutics, RCUS, ARQT, Astria Therapeutics, BDX, BLTE, BIIB, BRKR, TVRD.
- Vestal Point Capital was a net buyer of stock by $345M.
- Vestal Point Capital has $2.9B in assets under management (AUM), dropping by 32.82%.
- Central Index Key (CIK): 0001974915
Tip: Access up to 7 years of quarterly data
Positions held by Vestal Point Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Vestal Point Capital
Vestal Point Capital holds 76 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax SA Sponsored Ads (ABVX) | 8.7 | $256M | +90% | 1.9M | 134.85 |
|
| Invesco QQQ Trust Series 1 Unit Ser 1 Put Option (QQQ) | 7.3 | $215M | NEW | 350k | 614.31 |
|
| Arcellx Common Stock (ACLX) | 6.5 | $191M | +134% | 2.9M | 65.20 |
|
| Terns Pharmaceuticals (TERN) | 6.2 | $182M | NEW | 4.5M | 40.40 |
|
| BioMarin Pharmaceutical (BMRN) | 6.1 | $178M | +261% | 3.0M | 59.43 |
|
| Globus Medical Cl A (GMED) | 3.8 | $111M | +2% | 1.3M | 87.31 |
|
| Nurix Therapeutics (NRIX) | 3.0 | $89M | +34% | 4.7M | 18.97 |
|
| Alcon Ord Shs (ALC) | 3.0 | $87M | 1.1M | 78.81 |
|
|
| Dex (DXCM) | 2.9 | $85M | +96% | 1.3M | 66.37 |
|
| Merck & Co (MRK) | 2.8 | $82M | NEW | 775k | 105.26 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 2.6 | $76M | +150% | 14M | 5.50 |
|
| Abbott Laboratories (ABT) | 2.6 | $75M | +140% | 600k | 125.29 |
|
| Immatics NV SHS (IMTX) | 2.2 | $64M | -3% | 6.1M | 10.50 |
|
| Tyra Biosciences (TYRA) | 2.2 | $64M | 2.4M | 26.29 |
|
|
| Bicara Therapeutics (BCAX) | 2.0 | $60M | -29% | 3.6M | 16.83 |
|
| Arrowhead Pharmaceuticals (ARWR) | 2.0 | $60M | NEW | 900k | 66.39 |
|
| Enliven Therapeutics (ELVN) | 2.0 | $59M | +230% | 3.8M | 15.40 |
|
| Disc Medicine (IRON) | 2.0 | $58M | +47% | 735k | 79.41 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 1.7 | $49M | -42% | 290k | 170.00 |
|
| Day One Biopharmaceuticals I (DAWN) | 1.6 | $49M | +94% | 5.2M | 9.32 |
|
| Lexeo Therapeutics (LXEO) | 1.5 | $44M | +37% | 4.5M | 9.93 |
|
| Alto Neuroscience Com Shs (ANRO) | 1.5 | $44M | +161% | 2.5M | 17.80 |
|
| Apogee Therapeutics (APGE) | 1.4 | $42M | +29% | 550k | 75.48 |
|
| Olema Pharmaceuticals (OLMA) | 1.4 | $41M | NEW | 1.7M | 25.00 |
|
| Axsome Therapeutics (AXSM) | 1.3 | $38M | +40% | 210k | 182.64 |
|
| Ascendis Pharma A/S Sponsored Adr (ASND) | 1.3 | $37M | -70% | 175k | 213.24 |
|
| Rapport Therapeutics (RAPP) | 1.1 | $34M | +16% | 1.1M | 30.34 |
|
| Solid Biosciences Com New (SLDB) | 1.1 | $33M | +95% | 5.8M | 5.64 |
|
| Celldex Therapeutics Com New (CLDX) | 1.1 | $32M | -3% | 1.2M | 27.16 |
|
| Scholar Rock Hldg Corp (SRRK) | 1.0 | $31M | -53% | 700k | 44.05 |
|
| Kalvista Pharmaceuticals (KALV) | 1.0 | $31M | +152% | 1.9M | 16.15 |
|
| Vera Therapeutics Cl A (VERA) | 0.9 | $28M | -27% | 550k | 50.64 |
|
| Xenon Pharmaceuticals (XENE) | 0.9 | $27M | -45% | 600k | 44.82 |
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 0.8 | $24M | +111% | 360k | 66.55 |
|
| Revolution Medicines (RVMD) | 0.8 | $24M | -53% | 295k | 79.65 |
|
| Zymeworks Del (ZYME) | 0.8 | $23M | -50% | 865k | 26.33 |
|
| Immunocore Holdings Ads (IMCR) | 0.7 | $20M | NEW | 585k | 34.71 |
|
| Upstream Bio (UPB) | 0.7 | $20M | NEW | 720k | 27.15 |
|
| Beta Bionics (BBNX) | 0.6 | $18M | 600k | 30.47 |
|
|
| Crescent Biopharma (CBIO) | 0.6 | $18M | NEW | 1.5M | 11.86 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.6 | $18M | NEW | 2.3M | 7.80 |
|
| Penumbra (PEN) | 0.5 | $16M | NEW | 50k | 310.91 |
|
| Geron Corporation (GERN) | 0.5 | $15M | -34% | 11M | 1.32 |
|
| Repligen Corporation (RGEN) | 0.5 | $14M | -79% | 83k | 163.86 |
|
| Zimmer Holdings (ZBH) | 0.5 | $14M | NEW | 150k | 89.92 |
|
| Bristol Myers Squibb (BMY) | 0.5 | $14M | NEW | 250k | 53.94 |
|
| Monte Rosa Therapeutics (GLUE) | 0.4 | $12M | -3% | 775k | 15.68 |
|
| Fulcrum Therapeutics (FULC) | 0.4 | $11M | NEW | 950k | 11.31 |
|
| Savara (SVRA) | 0.3 | $9.7M | -60% | 1.6M | 6.03 |
|
| Engene Holdings (ENGN) | 0.3 | $9.5M | +185% | 1.1M | 9.03 |
|
| Agios Pharmaceuticals (AGIO) | 0.3 | $8.8M | +155% | 325k | 27.22 |
|
| Definium Therapeutics Com New (MNMD) | 0.3 | $8.5M | NEW | 637k | 13.39 |
|
| Denali Therapeutics (DNLI) | 0.3 | $7.7M | NEW | 465k | 16.51 |
|
| Myriad Genetics (MYGN) | 0.3 | $7.5M | +103% | 1.2M | 6.15 |
|
| Tectonic Therapeutic (TECX) | 0.2 | $6.8M | NEW | 328k | 20.86 |
|
| Novocure Ord Shs (NVCR) | 0.2 | $6.8M | +31% | 525k | 12.93 |
|
| Maplight Therapeutics (MPLT) | 0.2 | $6.8M | NEW | 385k | 17.57 |
|
| Gilead Sciences (GILD) | 0.2 | $6.1M | NEW | 50k | 122.74 |
|
| Voyager Therapeutics (VYGR) | 0.2 | $5.8M | 1.5M | 3.93 |
|
|
| DBV Technologies SA Sponsored Ads (DBVT) | 0.2 | $5.8M | NEW | 300k | 19.17 |
|
| Mirum Pharmaceuticals (MIRM) | 0.2 | $5.2M | NEW | 66k | 78.99 |
|
| Nyxoah SA SHS (NYXH) | 0.2 | $5.1M | 1.1M | 4.60 |
|
|
| Nuvalent Inc-a (NUVL) | 0.2 | $4.6M | -95% | 46k | 100.59 |
|
| Lenz Therapeutics (LENZ) | 0.1 | $4.4M | NEW | 275k | 16.00 |
|
| Rezolute Com New (RZLT) | 0.1 | $4.0M | NEW | 1.7M | 2.36 |
|
| Passage Bio Com New (PASG) | 0.1 | $3.6M | 305k | 11.80 |
|
|
| Sutro Biopharma Com Shs (STRO) | 0.1 | $2.8M | NEW | 243k | 11.57 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.1 | $2.4M | NEW | 35k | 69.55 |
|
| Dyne Therapeutics (DYN) | 0.1 | $2.3M | -95% | 120k | 19.56 |
|
| Black Diamond Therapeutics (BDTX) | 0.1 | $2.1M | -84% | 870k | 2.43 |
|
| OnKure Therapeutics Com Cl A (OKUR) | 0.1 | $1.8M | 635k | 2.90 |
|
|
| Fate Therapeutics (FATE) | 0.1 | $1.7M | -31% | 1.7M | 0.98 |
|
| Alector (ALEC) | 0.0 | $1.2M | -22% | 755k | 1.56 |
|
| Tenax Therapeutics Com New (TENX) | 0.0 | $651k | 53k | 12.19 |
|
|
| Regenxbio Inc equity us cm (RGNX) | 0.0 | $490k | NEW | 34k | 14.40 |
|
| Macrogenics (MGNX) | 0.0 | $451k | 280k | 1.61 |
|
Past Filings by Vestal Point Capital
SEC 13F filings are viewable for Vestal Point Capital going back to 2024
- Vestal Point Capital 2025 Q4 filed Feb. 17, 2026
- Vestal Point Capital 2025 Q3 filed Nov. 14, 2025
- Vestal Point Capital 2025 Q2 filed Aug. 14, 2025
- Vestal Point Capital 2025 Q1 filed May 15, 2025
- Vestal Point Capital 2024 Q4 filed Feb. 14, 2025
- Vestal Point Capital 2024 Q3 filed Nov. 14, 2024
- Vestal Point Capital 2024 Q2 filed Aug. 14, 2024